May 12, 2020
1 min read

Oyster Point Pharma meets primary endpoint in dry eye nasal spray study

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

A potential nasal spray treatment for dry eye signs and symptoms met its primary endpoint of increased Schirmer’s score in a phase 3 trial, Oyster Point Pharma announced in a press release.

The multicenter, double-masked, randomized, controlled ONSET-2 trial evaluated safety and efficacy of OC-01 (varenicline) nasal spray, a selective nicotinic acetylcholine receptor agonist, at two doses compared with vehicle in 758 patients.

Twice daily dosing of both a 0.6 mg/mL dose and a 1.2 mg/mL dose yielded statistically significant greater improvement of at least 10 mm on Schirmer’s score at 4 weeks compared to controls: 44% vs. 47% vs. 26%, respectively (P < .0001). Average increases in Schirmer’s scores were 11 mm in the 0.6 mg/mL group, 11.2 mm in the 1.2 mg/mL group and 5.9 mm in the control group.

The secondary endpoint of improvement in eye dryness score was met in the 1.2 mg/mL group at week 2 (P = .009) and week 4 (P = .002).

The company intends to submit a new drug application in 2020.